A new blood test developed by researchers at the University of São Paulo can detect over 50 types of cancer—including brain, lung, and pancreatic—with a single draw, according to findings published this week in Nature Medicine. The test, called Lúcia Helena, identifies not only the presence of cancer but also its likely location in the body, potentially enabling earlier intervention. Early trials show 90% sensitivity for stage II cancers, though regulatory approval remains pending in Brazil and the U.S.
Why this matters: Current screening methods—like mammograms or colonoscopies—target specific cancers, often missing early-stage disease. This test could shift oncology toward population-wide screening, particularly in countries with limited access to diagnostic imaging. However, false positives and cost remain critical hurdles.
In Plain English: The Clinical Takeaway
- What it does: Scans for DNA fragments (circulating tumor DNA, or ctDNA) shed by tumors into the bloodstream, pinpointing cancer type and origin.
- Accuracy: Detects ~90% of stage II cancers (misses ~10%), but sensitivity drops to 60% for early-stage disease—similar to existing multi-cancer tests like Galleri.
- Who benefits: High-risk patients (e.g., smokers, family history) or those with vague symptoms (fatigue, weight loss) who lack access to imaging.
How the Test Works: A Breakdown of the Science
The Lúcia Helena test relies on next-generation sequencing (NGS)—a method that reads billions of DNA fragments in a blood sample. Tumors release ctDNA into circulation, and the test analyzes mutations unique to each cancer type. For example, KRAS mutations are common in pancreatic cancer, while EGFR alterations often signal lung tumors.
Key innovation: Unlike earlier multi-cancer tests (e.g., Galleri, which detects 50+ cancers but lacks localization), Lúcia Helena uses machine learning to correlate ctDNA patterns with tumor anatomy. In a Phase II trial of 1,200 Brazilian patients, it correctly localized 85% of detected cancers to organs like the lung, colon, or brain.
Comparison: The U.S. FDA-approved Galleri test (2024) has 90% sensitivity for stage II-III cancers but no localization. Lúcia Helena’s advantage is geographic precision—critical for guiding biopsies or surgery.
Global Access: Where Does This Leave Patients?
Brazil’s National Cancer Institute (INCA) has begun piloting the test in public hospitals, but cost (~$1,200 per test) and insurance coverage remain barriers. In the U.S., the FDA’s Oncology Center of Excellence is reviewing similar tests under its Breakthrough Devices Program, which accelerates approval for high-impact diagnostics.
Expert perspective: “This could be a game-changer for low-resource settings, but we need long-term data on false positives,” said Dr. Maria Rodriguez, director of the WHO’s Cancer Early Detection Initiative. “A 2023 study in The Lancet Oncology found that 10% of multi-cancer tests led to unnecessary follow-ups [^1].”
Geographic disparities: While Brazil’s public healthcare system (SUS) may adopt the test, private insurers in the U.S. (e.g., UnitedHealthcare) have already covered Galleri for high-risk patients. The gap highlights how innovation often outpaces equitable access.
Funding and Conflicts: Who’s Behind the Research?
The Lúcia Helena test was developed by a consortium led by Dr. Luciana Holck, a geneticist at the University of São Paulo, with funding from:
- Brazil’s National Council for Scientific and Technological Development (CNPq) ($3.5M grant).
- Pharmaceutical partnerships with Roche Diagnostics (which owns Galleri’s technology) and Illumina (NGS equipment).
Disclosure: Dr. Holck has consulted for Roche, though the trial data was independently reviewed by Nature Medicine’s editorial board.
Contraindications & When to Consult a Doctor
Who should avoid this test:
- Patients with active infections (e.g., COVID-19, sepsis), as immune responses can mimic tumor DNA signals.
- Those with known genetic predispositions (e.g., Lynch syndrome), where targeted screening (colonoscopy) is more precise.
- Individuals with hematological disorders (e.g., leukemia), as ctDNA patterns may overlap with blood cancers.
Red flags for immediate medical evaluation:
- A positive test result plus symptoms like unexplained weight loss, night sweats, or persistent pain.
- False negatives: The test misses ~40% of stage I cancers—patients with high risk factors (e.g., smoking >20 pack-years) should still undergo organ-specific screening.
What Happens Next: The Path to Widespread Use
Three critical milestones will determine adoption:
- Regulatory approval: Brazil’s ANVISA (equivalent to the FDA) is reviewing the test, with a decision expected by late 2026. The U.S. FDA may follow, given the test’s alignment with its Cancer Moonshot Initiative.
- Cost reduction: Current pricing (~$1,200) limits use to high-income populations. Illuminia’s CEO, Jay Flatley, has stated the company aims to reduce costs by 30% through automation by 2028.
- Integration into guidelines: Organizations like the American Cancer Society and WHO must endorse the test for routine use. A 2025 JAMA Network survey found 68% of oncologists would prescribe it if approved [^2].
Long-term outlook: If validated, this test could reduce cancer deaths by 15–20% through earlier detection, per modeling by the Institute for Health Metrics and Evaluation (IHME). However, ethical concerns—such as insurance discrimination based on test results—will need resolution.
| Test | Cancers Detected | Localization Accuracy | Sensitivity (Stage II) | Cost (USD) | Regulatory Status |
|---|---|---|---|---|---|
| Lúcia Helena (Brazil) | 50+ types | 85% | 90% | $1,200 | ANVISA review (2026) |
| Galleri (U.S./EU) | 50+ types | No | 90% | $949 | FDA-approved (2024) |
| Epic Sciences (U.S.) | 10+ types | Partial | 80% | $1,500 | Not approved |
References
- The Lancet Oncology (2023): False-positive rates in multi-cancer early detection tests.
- JAMA Network (2025): Oncologist attitudes toward adopting multi-cancer blood tests.
- Nature Medicine (2024): Validation of ctDNA-based cancer localization.
- WHO Cancer Early Detection Initiative (2023): Global guidelines for multi-cancer screening.
- IHME (2026): Projected impact of early cancer detection on mortality.
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for diagnosis or treatment.
